EP3622088A1 — Biomarker for anti-tnf therapy in retinal diseases
Assigned to Hadasit Medical Research Services and Development Co · Expires 2020-03-18 · 6y expired
What this patent protects
The present invention is directed to a method for treating nvAMD in a subject having activated macrophages, using a macrophage modulating compound. Further provided are a diagnosis method and a kit for identifying a subject suitable for treatment using the macrophage modulating c…
USPTO Abstract
The present invention is directed to a method for treating nvAMD in a subject having activated macrophages, using a macrophage modulating compound. Further provided are a diagnosis method and a kit for identifying a subject suitable for treatment using the macrophage modulating compound.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.